Becton Dickinson Medical Technology (Jiangsu) Co., Ltd. (referred to as "BD Medical Yixing Plant") held its grand opening on December 18.Marks the official operation of BD Medical's third world-class local production base in China. Liu Ying, Deputy Mayor of Yixing Municipal People's Government, Party Secretary of Huanke Park, and Director of the Management Committee, Eric Borin, President of BD Medical’s Global Medication Delivery Solutions Business, Mo Linyao, Vice President of Pan-Asian Integrated Supply Chain, Zhu Xueliang, Vice President of Greater China Medication Delivery Solutions Business, and other government and enterprise leaders attended the opening ceremony to jointly witness this historic moment.

As a key part of BD's strategic layout in the Yangtze River Delta region, the Yixing plant not only embodies the company’s strategic vision for deeply expanding into the future medical market, but also represents an important milestone in the deepening practice of its localization strategy. Relying on the mature industrial chain and highly efficient logistics network in the Yangtze River Delta region, the plant aims to achieve full-chain localization from raw material supply, production, to market launch, with the goal of precisely meeting the growing and increasingly diversified demands of China’s healthcare market.

As the third world-class production base established by BD Medical in China and the core base for the localized production of FlowSmart®,Yixing Factory Achieves Significant Progress Recently. Last month, the Folex® production line at Yixing Factory was successfully launched and quickly achieved the first major sales milestone of one million units. Last week, Yixing People's Hospital officially adopted the first batch of Yixing-produced Folex® products, providing patients with safer and more efficient care services. These accomplishments not only mark another breakthrough in BD Medical’s localization strategy in the healthcare field in China but also reflect its firm commitment to the Chinese market and partners.

"In the journey to fully build a highland of the medical industry,Yixing has provided strong support and assistance to enterprises through a series of beneficial policies, promoting their orderly and stable development in the local market.The official completion and opening of BD's medical production base in Yixing not only marks a solid step forward in the deep cooperation between the two parties in the field of medical technology, but also carries our deep expectations. We look forward to fully leveraging Yixing's superior geographical location, strong industrial foundation, abundant talent resources, and robust scientific research capabilities to drive more innovative products to the entire country."

As the world's second-largest medical device market, China's demand for high-quality, high-performance medical devices and solutions continues to grow.Against this backdrop, China has built a complete medical device industry chain from raw material supply, component manufacturing to finished product assembly, providing opportunities for industrial chain collaboration and resource sharing for multinational companies such as BD.

BD Medical's Yixing Factory: A Total Investment of 1.332 Billion RMB, Covering 54 Mu with a Total Construction Area of 32,407 Square Meters. Upon Full Completion, the Annual Production Capacity is Expected to Reach 2.5 Million Liters of Bottled Injectables and 2.2 Billion Pre-filled Saline Syringes, with an Annual Output Value Projected to Exceed 2 Billion RMB. This Large-Scale Factory Not Only Demonstrates BD Medical’s Strong Confidence in the Chinese Market but Also Showcases Its Outstanding Strength in Localized Production and Supply Chain Optimization.

By establishing a local production base in China, BD is able to further integrate into the innovative development of China's medical industry chain and supply chain system, deeply understand the needs and preferences of local healthcare workers and patients, and develop products that better meet the demands of the Chinese market. At the same time, with the help of an efficient and intelligent production model, BD can effectively shorten product delivery cycles and improve market responsiveness, thereby enhancing market competitiveness. In addition, BD's establishment of a production base in China will also bring about a technology spillover effect, empowering the technical level and management capabilities of the local medical device industry, promoting technological innovation and industrial upgrading, and providing support for the overseas development of China's local medical device companies.

"Entering China for thirty years, BD Medical's localization development has welcomed one important milestone after another.""From the establishment of BD Suzhou Plant 1 in 1995, to the groundbreaking of BD Suzhou Plant 2 in 2008, and now to the opening of the Yixing plant today, each step demonstrates our determination and confidence in continuously expanding our presence in the Chinese market. The Yixing plant is equipped with world-leading fully automated production lines and will focus on the localized production of pre-filled catheter flush devices. As the second-largest market for BD globally, we will continue to explore more investment opportunities in China, collaborate with various local partners, and achieve more products manufactured in China to further fulfill our long-term commitment to the region."

"Innovation has always been the core driving force behind BD's pharmaceutical infusion business."BD continuously introduces the world's most advanced medical technologies and design concepts, developing a series of products that meet the needs of Chinese patients and medical institutions. Among them, the Folex® Prefilled Catheter Flush Syringe has been on the market in China for fifteen years. With its convenience, speed, and exclusive anti-blood reflux patent, it effectively reduces the risks of hospital-acquired infections and catheter blockages, earning widespread acclaim in clinical practice and becoming the preferred choice for many medical institutions. As an important base for the localized production of Folex®, the Yixing plant integrates top-tier manufacturing facilities and advanced production processes, ensuring the superior quality and reliable performance of Folex® products. At the same time, the plant will meet the urgent needs of a large number of infusion patients in China through approaches that are more closely aligned with local needs and efficiently responsive to the market, making a positive contribution to enhancing the overall efficiency of China’s healthcare system and the health and well-being of its people.

The establishment of BD Medical's Yixing plant has injected a strong new momentum into the park. It not only enriches the industrial ecosystem of the park but also promotes the efficiency improvement of the medical industry supply chain in the Yangtze River Delta region, bringing about wide-ranging and positive impacts. Meanwhile, the establishment of BD Medical's Yixing plant further fosters the formation of an industrial cluster effect. As the plant begins operations, more upstream and downstream enterprises are expected to be attracted here, forming closer industrial chain cooperation, thereby driving the healthcare industry in Yixing and even the entire Yangtze River Delta region to achieve faster and better development. Additionally, the plant has created a large number of job opportunities, providing local residents with more employment and career development prospects, further promoting regional economic prosperity and stability.

Since entering China in 1994, BD has adhered to the localized development philosophy of "Rooted in China, Serving China," continuously increasing its investment and localized layout in China. It has currently delivered 100,000 innovative products and is committed to actively building an innovative collaborative ecosystem in the medical technology industry. In addition to actively introducing globally leading innovative products and continuously meeting the diverse needs of China's healthcare system and patients, BD has established a robust infrastructure network in China comprising three local manufacturing plants, two R&D centers, six training centers, one customer service center, one customer experience center, and one innovation center. This network not only demonstrates BD's long-term commitment to the Chinese market but also highlights its positive role in enhancing local medical service standards and promoting the development of the healthcare industry.

BD Medical Successfully Integrates Advanced Technologies with the Needs of Chinese Patients through Its Localization Production Strategy. With the Grand Opening and Gradual Operation of Its Yixing Plant, BD Medical Will Further Deepen Its Local Innovation Layout to Promote High-Quality Development in China’s Healthcare Industry More Efficiently, Providing Stronger Support for Public Health and Contributing to the Achievement of the "Healthy China 2030" Goals. Moving Forward, BD Medical Will Continue to Uphold Its Core Values of "Innovation Leadership, Excellence in Quality, and Service First," Aiming to Introduce More Cutting-Edge Technologies and Innovative Products into China to Meet the Urgent Needs of a Wide Range of Patients. Through Concrete Actions, BD Medical Is Gradually Integrating Chinese Wisdom and Solutions into the Global Advancement and Development of the Medical Technology Industry.